Search Results
Vollenhoven, R. F. és mtsai: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis., 2009, 68 , 805
838 Nesbitt, A., Fossatti, G., Bergin, M. és mtsai: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents
, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional
829 838 Sandborn, W. J., Feagan, B. G., Stoinov, S. és mtsai: Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med., 2007, 357 , 228
. Lichtenstein GR , Thomsen OØ , Schreiber S , Lawrance IC , Hanauer SB , Hanauer SB , Bloomfield R , Sandborn WJ : Precise 3 Study Investigators: Continuous therapy with certolizumab pegol maintains remission of patients
., Lawrance, I. C., et al.: Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med., 2007, 357 , 239–250. Lawrance I. C. Maintenance therapy with certolizumab
818 824 Schreiber, S., Rutgeerts, P., Fedorak, R. N. és mtsai, CDP870 Crohn’s Disease Study Group: A randomized, placebo-controlled trial of certolizumab pegol